##### 



EXHIBIT 10.23
 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
 
          Affiliate
 Caskey Patents




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
 Field
 First Commercial Sale
 Indemnitee
 (a)
    
    ABBOTT, its directors, officers, employees and agents; and(b)
    
    BAYLOR, the Howard Hughes Medical Institute, their officers,
employees and agents, and the inventors of the Caskey patents.
 Licensed Process
 Licensed Product
 Valid Claim
      (a)
    
    One Million U.S. Dollars ($1,000,000) within thirty (30) days
of the Effective Date of this Agreement;
 -2-




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
 (b)
    
    One Million Two Hundred Fifty Thousand U.S. Dollars
($1,250,000) on or before December 31, 2006; and(c)
    
    One Million Two Hundred Fifty Thousand U.S. Dollars
($1,250,000) on or before July 1, 2007.
    
     (a)
    
    A partys obligations which have accrued prior to termination;(b)
    
    DIGENEs continuing obligation to indemnify the Indemnitees in
accordance with Article 7; and
 -3-




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
 (c)
    
    The parties continuing obligation to maintain the
confidentiality of the terms of this Agreement.
          -4-




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
        If to Abbott:
    
    Abbott Molecular Inc.1300 East Touhy AvenueDes Plaines, IL 60018Attention: Director of Licensing and Business DevelopmentFacsimile Number: 224.361.7054
 -5-




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
 With a copy to:
    
    Abbott LaboratoriesDept. 322, Bldg. AP6A/2100 Abbott Park RoadAbbott Park, IL 0064-6049Attention: Divisional Vice President,Medical Products Group Legal OperationsFacsimile Number: 847.938.1206If to DIGENE:
    
    Digene CorporationChief Executive Officer1201 Clopper RoadGaithersburg, Maryland 20878Facsimile Number: 301.944.7017With a copy to:
    
    Digene CorporationSenior Vice President, General Counsel and Secretary1201 Clopper RoadGaithersburg, MD 20878Facsimile Number: 240.632.7406
   (a)
    
    A bona fide purchaser of DIGENE as a result of a merger or
acquisition or asset purchase or of any of its Affiliates to which the
sublicense and rights pertain, provided that such bona fide purchaser agrees to
the terms and conditions of this Agreement; and(b)
    
    A wholly owned Affiliate of DIGENE.
     -6-




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
   Entire Agreement
 Amendment or Modification
 Survivability
 Counterparts
 Public Announcements
 Dispute Resolution
 -7-




---



##### 



THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED
MATERIAL IS MARKED WITH * AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
  ABBOTT LABORATORIES
    
    DIGENE CORPORATIONBy:
    
    /s/ Edward L. Michael
    
    By:
    
    /s/ Evan JonesEdward L. Michael
    
    
    
    Evan JonesPresident, Abbott Molecular
    
    
    
    Chief Executive Officer andChairmanDate: 6/28/06
    
    Date: 6/29/06
 -8-